Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 5 Jan 2019)

Research article
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences in their equivalence, manufacturing quality standards and reliability of supply. This necessitates reconsideration of the lowest price policy objective in pharmaceutical decision making. The aim of this study was to develop a Multi-Criteria Decision Analysis (MCDA) framework through a pilot workshop to inform the national procurement of OPPs in Indonesia.
Authors: Andras Inotai, Diana Brixner, Nikos Maniadakis, Iwan Dwiprahasto, Erna Kristin, Agus Prabowo, Alfi Yasmina, Sigit Priohutomo, Bertalan Németh, Kalman Wijaya and Zoltan Kalo
Citation: BMC Health Services Research 2018 18:1003
Published on: 29 December 2018